Wrap Text
Notification of transactions by persons discharging managerial responsibilities and persons closely associated
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
('Mediclinic', or the 'Company', or the 'Group')
24 November 2022
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
This notification sets out details of the vesting of awards over ordinary shares in the Company granted
to the executive directors of the Company in respect of the deferred element of the short-term incentive
('STI') scheme pay-out for the financial year ended 31 March 2020 (the 'FY20 STI Awards').
The awards vested on 21 November 2022 and will be settled in cash, based on the closing middle–
market quotation of a share on the London Stock Exchange on 21 November 2022, being 495.2 pence
per share.
The table below sets out the number of shares vested under the FY20 STI Awards, together with the
corresponding cash settlement. The amount settled includes the value of dividends attributable to the
vested shares during the period between the date of grant and the date of vesting, being a total of 3.00
pence per share.
Name Number of shares Cash settlement (including
vested under the dividend equivalents)
FY20 STI Awards
Dr Carel Aron van der Merwe 20 391 £101 589
(Group Chief Executive Officer)(1)
Petrus Jurgens Myburgh 13 383 £66 675
(Group Chief Financial Officer)(1)
The notifications that follow are made in accordance with Articles 19.1 and 19.3 of the Market Abuse
Regulation.
1. Details of person discharging managerial responsibilities ('PDMR') / person closely
associated with them ('PCA')
a) Name Dr Carel Aron van der Merwe
2. Reason for the notification
a) Position / status Group Chief Executive Officer
b) Initial notification / Initial notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or
auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Vesting and cash settlement of award over ordinary shares in
transaction Mediclinic International plc granted in 2020 under the
Company’s STI scheme
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 20 391
d) Aggregated
information
Aggregated volume 20 391
Price £nil
e) Date of the 21 November 2022
transaction
f) Place of the Outside a trading venue
transaction
1. Details of PDMR / PCA
a) Name Petrus Jurgens Myburgh
2. Reason for the notification
a) Position / status Group Chief Financial Officer
b) Initial notification / Initial notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or
auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each
type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the Vesting and cash settlement of award over ordinary shares in
transaction Mediclinic International plc granted in 2020 under the
Company's STI scheme
c) Price(s) and
volume(s) Price(s) Volume(s)
£nil 13 383
d) Aggregated
information
Aggregated volume 13 383
Price £nil
e) Date of the 21 November 2022
transaction
f) Place of the Outside a trading venue
transaction
ABOUT MEDICLINIC INTERNATIONAL PLC
Mediclinic is a diversified international private healthcare services group, established in South Africa in 1983, with
divisions in Switzerland, Southern Africa (South Africa and Namibia) and the Middle East.
The Group's core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum of care in
such a way that the Group will be regarded as the most respected and trusted provider of healthcare services by
patients, medical practitioners, funders and regulators of healthcare in each of its markets.
At 30 September 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, three mental health facilities,
21 day case clinics and 23 outpatient clinics. Hirslanden operated 17 hospitals and five day case clinics in
Switzerland with around 1 900 inpatient beds; Mediclinic Southern Africa operations included 50 hospitals (three
of which in Namibia), five subacute hospitals, three mental health facilities and 14 day case clinics (four of which
operated by Intercare) across South Africa, and around 8 700 inpatient beds; and Mediclinic Middle East operated
seven hospitals, two day case clinics and 23 outpatient clinics with around 1 000 inpatient beds in the UAE. In
addition, under management contract Mediclinic Middle East will open a 200-bed hospital in the Kingdom of Saudi
Arabia in 2023.
The Company's primary listing is on the London Stock Exchange ('LSE') in the United Kingdom, with secondary
listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.7% (2022: 29.9%) interest in Spire Healthcare Group plc, a leading private healthcare
group based in the United Kingdom and listed on the LSE.
CONTACT INFORMATION
Investor queries
James Arnold, Head of Investor Relations, Mediclinic International plc
+44 (0)20 3786 8181
ir@mediclinic.com
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Joint corporate brokers: Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Ltd)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 24-11-2022 05:40:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
